Skip to main content
. 2021 Sep 14;18(9):e1003738. doi: 10.1371/journal.pmed.1003738

Fig 2. Duration of treatment and posttreatment follow-up of the included studies.

Fig 2

Notes: Study arms are abbreviated by the number of months and treatment regimens (H, isoniazid; P, rifapentine; Pbo, placebo; R, rifampin; NT, no treatment). ª WHO TB burden estimates for all forms of TB (cases/100,000 people, year). b Treatment arms considered not of interest were excluded in this figure for simplicity. † Mean or median follow-up of the planned continuous isoniazid regime. TB, tuberculosis; WHO, World Health Organization.